Quick Links

Accreditation/Credit Designation

Physicians' Education Resource®, LLC (PER®), is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

This activity is supported and entirely funded by PER.

Community Practice Connections™: 2nd Annual European Symposium on Lung Cancers™

Release Date: August 30,, 2018
Expiration Date: August 30, 2019
Media: Internet - based

Activity Overview

Community Practice Connections: 2nd Annual European Symposium on Lung Cancers features a summary of clinical evidence guiding best practices in the treatment of patients with non–small cell lung cancer (NSCLC), including recent developments with targeted agents and immunotherapy. Interactive clinical vignettes are followed by short video interviews with internationally renowned experts in the management of patients with NSCLC. The video interviews address decision points in the clinical vignettes and questions commonly faced in the community oncology practice setting by medical professionals engaged in the care of patients with NSCLC.

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, and other healthcare professionals involved in the treatment and management of patients with lung cancer.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Discuss state-of-the-art application of immunotherapy in metastatic non-small cell lung cancer (NSCLC)
  • Describe the emergence of immunotherapy in locally advanced NSCLC
  • Review new standards for patients with EGFR-mutated and ALK-rearranged NSCLC, and recent data on therapies to target other oncogenic drivers
  • Understand the role of liquid biopsies for treatment selection
  • Describe the pulmonologist’s perspective on best practices in lung cancer diagnosis and therapy
  • Gain insight into the therapeutic advances in small cell lung cancer (SCLC) and mesothelioma

Faculty, Staff, and Planners' Disclosure

Benjamin Besse, MD, PhD
Head of the Cancer Medicine Department
Gustave Roussy
Villejuif, France

Disclosure: Grant/Research Support: AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Lilly, Pfizer, Roche/Genentech, sanofi-aventis, Clovis, GlaxoSmithKline, Servier, EOS Pharmaceutical Corp., Onxeo, OncoMed, Inivata, OSE Pharma

Prof. Dr. med. Martin Reck
Head of the Thoracic Oncology and Clinical Trial Departments
LungenClinic Grosshansdorf
Grosshansdorf, Germany

Disclosure: Consultant/Advisory Board:Roche, Lilly, AstraZeneca, Merck Sharp & Dohme, Bristol-Myers Squibb, Boehringer Ingelheim, Pfizer, Novartis, Celgene; Speakers Bureau: Roche, Lilly, AstraZeneca, Merck Sharp & Dohme, Bristol-Myers Squibb, Boehringer Ingelheim, Pfizer, Novartis, Celgene

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. ACCME defines relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest (COI).
Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Become a Member

Forgot Password?
Calendar of Events
Filter By